Video Experimental Relacionado
Updated: Jul 13, 2026
20:16
Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
La suplementación con progestágenos de estrógenos exógenos y el riesgo de cáncer de endometrio
Lancet (London, England)
|August 3, 1991
Resumen
El uso de progestágenos, especialmente durante 10 o más días por ciclo, reduce significativamente el aumento del riesgo de cáncer de endometrio relacionado con la terapia de estrógeno sin oposición a largo plazo en mujeres posmenopáusicas.
Área de la Ciencia:
- Ginecología Ginecología.
- Oncología Oncología.
- Epidemiología La epidemiología.
Sus antecedentes:
- Los beneficios endometriales del progestágeno exógeno están establecidos pero no totalmente cuantificados para el riesgo de cáncer endometrial.
- Los beneficios del progestageno deben ser equilibrados con los riesgos potenciales de cáncer de mama y enfermedades cardiovasculares.
- Comprender el papel del progestágeno en la mitigación del cáncer de endometrio inducido por estrógeno es crucial para el manejo de la terapia hormonal.
Objetivo del estudio:
- Cuantificar el efecto protector del uso de progestágenos contra el cáncer de endometrio en mujeres que utilizan terapia hormonal.
- Para evaluar la relación dosis-respuesta entre la duración del uso de progestagenos y el riesgo de cáncer de endometrio.
Principales métodos:
- Un estudio de casos y controles basado en la población que involucró a 158 casos de cáncer de endometrio y 182 controles (mujeres de 40-64 años).
- Recopilación de datos a través de entrevistas detalladas sobre el uso de la terapia hormonal, incluidos los estrógenos y los progestagenos.
- Análisis estadístico para calcular los riesgos relativos (RR) y los intervalos de confianza (IC) para el cáncer de endometrio asociado con diferentes regímenes hormonales.
Principales resultados:
- Las mujeres que usaban estrógeno sin oposición durante más de 3 años tenían un riesgo 5,7 veces mayor de cáncer de endometrio en comparación con las no usuarias.
- El uso simultáneo de progestágenos durante al menos seis meses redujo este riesgo a un RR de 1,6.6.
- El uso de progestágenos durante 10 o más días por ciclo mostró un RR significativamente menor (1.1) en comparación con menos de 10 días (2.4).
Conclusiones:
- El uso de progestágenos, particularmente durante 10 o más días por ciclo, mitiga efectivamente el elevado riesgo de cáncer de endometrio asociado con la terapia de estrógeno posmenopáusica a largo plazo.
- Estos hallazgos apoyan el uso de la terapia hormonal combinada (estrógeno con progestageno) para mejorar la seguridad endometrial.
- Investigaciones adicionales pueden explorar regímenes óptimos de progestageno para maximizar la protección endometrial y minimizar otros riesgos potenciales.
Videos de Conceptos Relacionados
01:41Spermatogenesis
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male reproductive...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:24Gonadal and Placental Hormones
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...